Lippoldt Darin

Lippoldt Darin, Chief Legal Officer at Neurocrine Biosciences (NBIX), has been a consistent seller of company stock over the past year, with no open-market purchases recorded in his SEC Form 4 filings. Across 43 transactions, all concentrated in NBIX, his total sell value reached approximately $6.74 million, while his acquired value from exercises and awards stood at zero. The most recent activity, spanning June and July 2026, shows a clear pattern: on July 9, he sold shares worth $1.80 million, paired with an option exercise valued at $814,900; on June 29, he executed two sales totaling $1.67 million alongside exercises worth $798,602; and on June 26, a smaller sale of $33,913 accompanied a $16,298 exercise. These transactions, all coded as open-market sales (S) and option exercises (M), reflect a systematic liquidation of vested shares rather than discretionary buying. The selling bias is unambiguous, but the mechanics matter. Every sale in the recent window is matched with an M-code exercise, meaning Lippoldt is converting options into stock and immediately disposing of it—a routine pattern for executives monetizing compensation. The February 2026 filings reinforce this: he received multiple A-code grants (valued at $0) and G-code gifts, while F-code tax-withholding transactions totaled over $1.06 million, indicating shares were automatically surrendered to cover tax obligations on vesting. No P-code purchases appear anywhere in his history, so his only discretionary market activity is selling. The December 2025 sale of $698,615, also paired with an exercise, extends this trend backward, showing consistent quarterly monetization. What the data does not show is any signal of conviction buying. Lippoldt’s total buy value is zero, and his recent six trades are all sells, with the largest single disposition—$1.80 million on July 9, 2026—representing over a quarter of his cumulative sell volume. The pattern is mechanical: exercise, sell, and pay taxes, with no accumulation phase. For investors tracking insider sentiment, the absence of purchases in a single-stock portfolio is notable, but the regularity of the sales suggests a pre-planned compensation strategy rather than a reaction to company performance. The dollar values are substantial, but they track option expirations and vesting schedules, not market timing.